Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Cash from Financing Activities for 5 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 1058.92% year-over-year to -$1.8 million, compared with a TTM value of $27.5 million through Sep 2025, down 95.09%, and an annual FY2024 reading of $589.6 million, up 66867.16% over the prior year.
  • Cash from Financing Activities was -$1.8 million for Q3 2025 at Autolus Therapeutics, down from -$768000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $561.4 million in Q1 2024 and bottomed at -$2.1 million in Q2 2024.
  • Average Cash from Financing Activities over 4 years is $73.6 million, with a median of $4000.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 130365.22% in 2024, then crashed 1058.92% in 2025.
  • Year by year, Cash from Financing Activities stood at $223.5 million in 2022, then tumbled by 99.99% to $23000.0 in 2023, then soared by 130365.22% to $30.0 million in 2024, then crashed by 105.91% to -$1.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AUTL at -$1.8 million in Q3 2025, -$768000.0 in Q2 2025, and $30.0 million in Q4 2024.